Gastric cancer: using pretreatment CT and clinical data to predict outcomes
Official title: Prospective Validation of a CT Radiomics-Based Model Combined With Clinical Features for Prognosis Prediction in Gastric Cancer Patients
Run by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · NCT07776067 · Data updated 2026-11-12
A previously developed CT-based model that combines imaging features with clinical data is being tested to see if it can predict survival and progression in adults with gastric cancer before treatment.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 600 (estimated) |
| Sponsor | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy |
| Locations | 1 site (Wuhan, Hubei) |
| Status | Recruiting |
| Started | April 1, 2026 |
| Main results expected | April 1, 2027 |
| Study ends | April 1, 2027 |
| Registry record updated | August 31, 2026 |
| Trial ID | NCT07776067 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18+) with histologically confirmed gastric cancer receiving treatment at the study center and with complete pretreatment CT data.
✕Probably not a fit
Patients without high‑quality pretreatment CT data or with incomplete clinical information may not benefit from the model's predictions.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a prospective, single‑center observational study to validate a prognostic model that merges pretreatment CT image features with routine clinical information. Adults with newly diagnosed gastric cancer who are about to receive surgery, chemotherapy, immunotherapy, or a combination are enrolled and followed during standard care. Data such as pretreatment CT scans, demographics, tumor characteristics, lab results, treatment details, and outcomes are collected to compare model predictions with actual outcomes using survival analyses and Cox regression. The study does not alter usual treatment and focuses on assessing prognostic performance and risk stratification across subgroups defined by treatment, stage, age, and sex.
Why it matters
Potential benefit: If successful, the model could help doctors estimate prognosis more accurately and tailor follow‑up and counseling for gastric cancer patients.
How similar studies have gone: Previous retrospective work forming the model suggested prognostic value, and this prospective validation tests whether those findings hold in routine care.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Histologically or pathologically confirmed gastric cancer and receiving treatment at the study center. * Age ≥18 years. * Complete pretreatment CT imaging data available from the study center. Exclusion Criteria: * Pretreatment CT images of insufficient quality for analysis. * Incomplete clinical data. * Presence of another malignant tumor in addition to gastric cancer.
Where it's running
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
CG-7321: a first-in-human test in advanced solid tumors
We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.
-
Neoadjuvant trastuzumab, durvalumab, and FLOT for HER2-positive gastric or GEJ cancer
This study tests a pre-surgery treatment combining trastuzumab, durvalumab, and FLOT for patients with HER2-positive locally advanced gastric or gastroesophageal junction cancer to see how many achieve complete tumor disappearance.
-
Integrated genomic and clinical database for cancer biomarker discovery
Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.
-
Adding 2141-V11 to standard therapy for advanced esophageal, gastric, or gastroesophageal junction cancer
This study tests whether adding the drug 2141-V11 to standard anti-PD-1 therapy (with or without 5-FU) is safe for adults with advanced or metastatic esophageal, gastric, or gastroesophageal junction adenocarcinoma.
-
Guaraná Supplement for Cancer-Related Fatigue in People Undergoing Treatment
This study tests whether taking guaraná capsules helps reduce cancer-related fatigue and improve quality of life in adults with breast, lung, colorectal, or gastric cancer who are actively receiving treatment.
-
ABBV-253 in adults with advanced solid tumors
This study tests ABBV-253 to see if it is safe, how it affects the cancer, and how the drug moves in the body for adults with advanced solid tumors.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.